SARS-CoV-2 infection: use and effectiveness of antigenic swab for the health surveillance of healthcare workers.


Journal

La Medicina del lavoro
ISSN: 0025-7818
Titre abrégé: Med Lav
Pays: Italy
ID NLM: 0401176

Informations de publication

Date de publication:
23 Dec 2021
Historique:
received: 06 08 2021
accepted: 09 11 2021
entrez: 23 12 2021
pubmed: 24 12 2021
medline: 25 12 2021
Statut: epublish

Résumé

 The gold standard to identify SARS-CoV-2 infections is the Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) on rhino-pharyngeal swabs, but faster and cheaper methods such as antigenic swabs have been developed. A retrospective observational study on antigenic swabs included in the extraordinary health surveillance protocol of a large Hospital in Turin was aimed to assess their performance validity. Methods: From 30 October 2020 to 4 May 2021, 4000 antigenic swabs were carried out in three groups of healthcare workers (HCWs), respectively (i) asymptomatic, (ii) cohabiting with a positive case, and (iii) not recently exposed to the virus.  Results: Overall sensitivity and specificity associated with a prevalence of 1.30% were 26.9%, 97.2%, respectively, the corresponding positive (PPV) and negative predictive value (NPV) being 11.29% and 99.02% [95% IC (99.00 - 99.04)] respectively; a prevalence of 0.29% was observed in the asymptomatic group, among whom sensitivity and specificity were 25.0% and 98.9%, respectively, the corresponding PPV and NPV being 6.25% and 99.78% [95% IC (99.76 - 99.81)], respectively; the cohabitant group showed a prevalence of 21.11%, sensitivity and specificity were 47.4%, 81.7%, respectively, giving rise to a PPV of 40.91% and NPV of 85.29% [95% IC (85.18 - 85.41)] respectively. The prevalence in the not exposed group was 0.77%, sensitivity and specificity were 29.2%, 97.4%, respectively, and PPV and NPV 8.05% and 99.44% [95% IC (99.42 - 99.46)] respectively. Conclusions: Antigenic swabs reduced costs and provided reliable diagnostic results. In the cohabitant group, the higher-prevalence groups showed poor test performances, likely because of the high prevalence of pre-symptomatic illness in this group. Owing to the relatively low NPV, a negative result would still require confirmation with a molecular test to be acceptable for a surveillance program that effectively reduces the virus's intra-hospital spread.

Sections du résumé

BACKGROUND BACKGROUND
 The gold standard to identify SARS-CoV-2 infections is the Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) on rhino-pharyngeal swabs, but faster and cheaper methods such as antigenic swabs have been developed. A retrospective observational study on antigenic swabs included in the extraordinary health surveillance protocol of a large Hospital in Turin was aimed to assess their performance validity. Methods: From 30 October 2020 to 4 May 2021, 4000 antigenic swabs were carried out in three groups of healthcare workers (HCWs), respectively (i) asymptomatic, (ii) cohabiting with a positive case, and (iii) not recently exposed to the virus.  Results: Overall sensitivity and specificity associated with a prevalence of 1.30% were 26.9%, 97.2%, respectively, the corresponding positive (PPV) and negative predictive value (NPV) being 11.29% and 99.02% [95% IC (99.00 - 99.04)] respectively; a prevalence of 0.29% was observed in the asymptomatic group, among whom sensitivity and specificity were 25.0% and 98.9%, respectively, the corresponding PPV and NPV being 6.25% and 99.78% [95% IC (99.76 - 99.81)], respectively; the cohabitant group showed a prevalence of 21.11%, sensitivity and specificity were 47.4%, 81.7%, respectively, giving rise to a PPV of 40.91% and NPV of 85.29% [95% IC (85.18 - 85.41)] respectively. The prevalence in the not exposed group was 0.77%, sensitivity and specificity were 29.2%, 97.4%, respectively, and PPV and NPV 8.05% and 99.44% [95% IC (99.42 - 99.46)] respectively. Conclusions: Antigenic swabs reduced costs and provided reliable diagnostic results. In the cohabitant group, the higher-prevalence groups showed poor test performances, likely because of the high prevalence of pre-symptomatic illness in this group. Owing to the relatively low NPV, a negative result would still require confirmation with a molecular test to be acceptable for a surveillance program that effectively reduces the virus's intra-hospital spread.

Identifiants

pubmed: 34939621
doi: 10.23749/mdl.v112i6.12125
pmc: PMC8759044
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

444-452

Références

N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Med Lav. 2021 Oct 28;112(5):331-339
pubmed: 34726663
J Clin Virol. 2021 Jun;139:104838
pubmed: 33946040
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Med Lav. 2021 Jun 15;112(3):183-193
pubmed: 34142672
Int J Mol Med. 2021 Jun;47(6):
pubmed: 33846767
Med Lav. 2021 Oct 28;112(5):340-345
pubmed: 34726662
J Virol Methods. 2021 Sep;295:114201
pubmed: 34058287
Med Lav. 2020 Jun 26;111(3):184-194
pubmed: 32624560
MMWR Morb Mortal Wkly Rep. 2021 May 14;70(19):702-706
pubmed: 33983916
Rev Esp Quimioter. 2020 Dec;33(6):466-484
pubmed: 33070578
Infect Dis Ther. 2021 Jun;10(2):753-761
pubmed: 33629225

Auteurs

Maurizio Coggiola (M)

Department of Occupational Medicine, University Hospital Città della Salute e della Scienza di Torino. maurizio.coggiola@unito.it.

Rossana Cavallo (R)

Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino. rossana.cavallo@unito.it.

Eugenio Grillo (E)

. eugenio.grillo@unito.it.

Roberto Frammartino (R)

Department of Occupational Medicine, University Hospital Città della Salute e della Scienza di Torino. roberto.frammartino@unito.it.

Giuseppe Clemente (G)

Department of Occupational Medicine, University Hospital Città della Salute e della Scienza di Torino. giuseppe.clemente@unito.it.

Cristina Costa (C)

Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino. cristina.costa@unito.it.

Ida Marina Raciti (IM)

Quality, Risk Management and Accreditation, University Hospital Città della Salute e della Scienza di Torino. iraciti@cittadellasalute.to.it.

Carlo Silvestre (C)

Health Management Molinette Hospital, University Hospital Città della Salute e della Scienza di Torino. csilvestre@cittadellasalute.to.it.

Gitana Scozzari (G)

Health Management Molinette Hospital, University Hospital Città della Salute e della Scienza di Torino. gscozzari@cittadellasalute.to.it.

Ettore Paradisi (E)

Department of Occupational Medicine, University Hospital Città della Salute e della Scienza di Torino. ettore.paradisi@unito.it.

Alessandro Tuffanelli (A)

Department of Occupational Medicine, University Hospital Città della Salute e della Scienza di Torino. alessandro.tuffanelli@unito.it.

Maria Carolina Alfonso Pensamiento (MC)

Department of Occupational Medicine, University Hospital Città della Salute e della Scienza di Torino. mariacarolina.alfonsopensamiento@unito.it.

Alessandro Godono (A)

Department of Occupational Medicine, University Hospital Città della Salute e della Scienza di Torino. alessandro.godono@unito.it.

Enrico Pira (E)

Department of Occupational Medicine, University Hospital Città della Salute e della Scienza di Torino. enrico.pira@unito.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH